CRM1

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S7252 Selinexor (KPT-330) <1 mg/mL 89 mg/mL 40 mg/mL
S7125 KPT-185 <1 mg/mL 71 mg/mL 71 mg/mL
S7251 KPT-276 <1 mg/mL 20 mg/mL <1 mg/mL
S7707 Verdinexor (KPT-335) <1 mg/mL 88 mg/mL 11 mg/mL
S7551 Piperlongumine <1 mg/mL 16 mg/mL 6 mg/mL
Catalog No. Information Product Use Citations Product Validations
S7252

Selinexor (KPT-330)

Selinexor (KPT-330) is an orally bioavailable selective CRM1 inhibitor. Phase 2.

S7125

KPT-185

KPT-185 is a selective CRM1 inhibitor that induces growth inhibition and apoptosis in a panel of NHL cell lines with a median IC50 ~25 nM.

S7251

KPT-276

KPT-276 is an orally bioavailable selective CRM1 inhibitor.

S7707

Verdinexor (KPT-335)

Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

S7551

Piperlongumine

Piperlongumine, a natural alkaloid from Piper longum L., increases the level of reactive oxygen species (ROS) and selectively kills cancer cells. It is a direct TrxR1 inhibitor with suppressive activity against gastric cancer and a novel inhibitor of CRM1; also an inhibitor of PI3K/Akt/mTOR in human breast cancer cells.

Catalog No. Information Product Use Citations Product Validations
S7252

Selinexor (KPT-330)

Selinexor (KPT-330) is an orally bioavailable selective CRM1 inhibitor. Phase 2.

S7125

KPT-185

KPT-185 is a selective CRM1 inhibitor that induces growth inhibition and apoptosis in a panel of NHL cell lines with a median IC50 ~25 nM.

S7251

KPT-276

KPT-276 is an orally bioavailable selective CRM1 inhibitor.

S7707

Verdinexor (KPT-335)

Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

Catalog No. Information Product Use Citations Product Validations
S7551

Piperlongumine

Piperlongumine, a natural alkaloid from Piper longum L., increases the level of reactive oxygen species (ROS) and selectively kills cancer cells. It is a direct TrxR1 inhibitor with suppressive activity against gastric cancer and a novel inhibitor of CRM1; also an inhibitor of PI3K/Akt/mTOR in human breast cancer cells.

2016, 10.18632/oncotarget.10921

2016, 7(26):40531-40545